Outcomes of Dupilumab treatment in patients presenting with severe asthma or chronic rhinosinusitis with nasal polyps, over the age of 65

Keisha Arielle Best
Wayne State University, gc6036@wayne.edu

Samiat Awosanya
Thomas Jefferson University Hospital

Chandala Chitguppi
Thomas Jefferson University Hospital

Marc Rosen
Thomas Jefferson University Hospital

Mindy Rabinowitz
Thomas Jefferson University Hospital

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wayne.edu/som_srs

Part of the Otolaryngology Commons

Recommended Citation
Best, Keisha Arielle; Awosanya, Samiat; Chitguppi, Chandala; Rosen, Marc; Rabinowitz, Mindy; Toskala, Elina; Nyquist, Gurston; and Most, Jessica, "Outcomes of Dupilumab treatment in patients presenting with severe asthma or chronic rhinosinusitis with nasal polyps, over the age of 65" (2023). Medical Student Research Symposium. 225.
https://digitalcommons.wayne.edu/som_srs/225

This Research Abstract is brought to you for free and open access by the School of Medicine at DigitalCommons@WayneState. It has been accepted for inclusion in Medical Student Research Symposium by an authorized administrator of DigitalCommons@WayneState.
Authors
Keisha Arielle Best, Samiat Awosanya, Chandala Chitguppi, Marc Rosen, Mindy Rabinowitz, Elina Toskala, Gurston Nyquist, and Jessica Most

This research abstract is available at DigitalCommons@WayneState: https://digitalcommons.wayne.edu/som_srs/225
Outcomes of Dupilumab treatment in patients presenting with severe asthma or chronic rhinosinusitis with nasal polyps, over the age of 65

K. Arielle Best, MS¹; Samiat Awosanya, MS¹; Chandala Chitguppi, MD¹; Marc Rosen, MD¹; Mindy Rabinowitz, MD¹; Elina Toskala, MD¹; Gurston Nyquist, MD¹; Jessica Most, MD²
¹Department of Otolaryngology- Head and Neck Surgery, Thomas Jefferson University Hospital
²Department of Pulmonology, Thomas Jefferson University Hospital

Introduction:
Dupilumab is an IL-4/13 inhibitor that has been successfully implemented in the treatment of severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The safety and efficacy of Dupilumab has not been reported for these indications in patients over the age of 65. This study aims to determine the long-term benefits of dupilumab while detailing adverse effects.

Methods:
This study is a single institution retrospective review of patients receiving dupilumab for severe asthma and/or CRSwNP from 2018 to present. Charts were reviewed for patient demographics, Sino-nasal Outcome Test (SNOT-22) scores, asthma control test (ACT) scores, polyp scores, and adverse effects. We reported the findings of patients over the age of 65 whose first biologic was dupilumab.

Results:
Thirty-one patients over the age of 65 were identified (mean = 72.2), 18 (58.1%) of whom are female. Twelve (38.7%) presented with severe asthma, 7 (22.6%) with CRSwNP and 12 (38.7%) with both severe asthma and CRSwNP.

Compared to baseline, there was a significant difference observed within patients in mean ACT (17.8 to 20.3; n=13, p=0.002), SNOT-22 (40.5 to 23.4; n=10, p=0.015), and polyp scores (3.06 to 1.13; n=8, p=0.010) post-treatment initiation.

Seven patients (22.6%) reported adverse reactions that may or may not be related to dupilumab. Adverse reactions included ophthalmologic (1), musculoskeletal (1), dermatologic (2) and other (2) which included lower extremity edema, tinnitus, hair loss, and TMJ pain. Zero patients reported allergic reactions. Four of the 7 patients who experienced adverse reactions chose to continue dupilumab therapy, while 3 discontinued.

Conclusions:
Patients over 65 on dupilumab showed improvement in asthma and CRSwNP symptoms. There were significant improvements in ACT, SNOT-22, and nasal polyp scores within 9 months of therapy initiation. The majority did not experience any adverse effects, demonstrating the value of dupilumab treatment in this patient cohort.